Independent Medical Education (IME)

Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Opportunity:

• Spinal muscular atrophy (SMA) is a neuromuscular disorder affecting both children and adults. The development of disease-modifying therapies within the past 5 years has moved disease management beyond purely supportive care approaches. It is important to help healthcare providers understand how to personalize therapeutic and supportive care plans for adult SMA patients.
• The transition of care from childhood to adulthood is an important consideration for individualizing treatment. There are many factors for a multidisciplinary team to consider beyond therapy alone, such as the physical, psychosocial, and logistical aspects of care for these adult SMA patients.
• Genentech would like to support independent medical education that addresses the current treatment landscape for adult SMA patients and the necessary considerations for the transition to adult care for SMA patients.
  

Genentech supports grants for independent medical education in an effort to advance excellence in medicine and healthcare and improve patient health outcomes by enhancing the knowledge of the medical community.

Independent Medical Education (IME) is generally defined as education for healthcare professionals (HCPs) provided by an independent educational provider, such as a community hospital, academic center, society/association or medical education and communication company.

For information on funding priorities, see the Full Grant Text (RFP) link listed below.